Latest Posts › Life Sciences

Share:

Horizon Medicines LLC v. Alkem Labs. Ltd.

Duexis® (ibuprofen / famotidine) - Case Name: Horizon Medicines LLC v. Alkem Labs. Ltd., No. 18-1014-RGA, 2020 WL 7022591 (D. Del. Nov. 30, 2020) (Andrews, J.) ...more

Tris Pharma, Inc. v. Actavis Labs. FL, Inc.

Quillivant XR® (methylphenidate (“MPH”)) - Case Name: Tris Pharma, Inc. v. Actavis Labs. FL, Inc., No. 14-1309-CFC, 2020 WL 7028456 (D. Del. Nov. 30, 2020) (Connolly, J.)...more

Encore Dermatology Inc. v. Glenmark Pharms. Ltd.

Impoyz® (clobetasol) - Case Name: Encore Dermatology Inc. v. Glenmark Pharms. Ltd., Civ. No. 20-02509 (KM) (ESK), 2020 WL 7586958 (D.N.J. Dec. 22, 2020) (McNulty, J.)...more

GlaxoSmithKline LLC v. Teva Pharms. USA, Inc.

Coreg® (carvedilol) - Case Name: GlaxoSmithKline LLC v. Teva Pharms. USA, Inc., No. 2018-1976, -2023 (Fed. Cir. Oct. 2, 2020) (Circuit Judges Prost, Newman, and Moore presiding; Opinion by Newman, J.; Dissent by Prost, C.J.)...more

Valeant Pharm. N. Am. LLC v. Mylan Pharm. Inc.

Jublia® (efinaconazole) - Case Name: Valeant Pharm. N. Am. LLC v. Mylan Pharm. Inc.,978 F.3d 1374 (Fed. Cir. Nov. 5, 2020)(Circuit Judges Newman, O’Malley, and Taranto presiding; Opinion by O’Malley, J.) (Appeal from D.N.J.,...more

New ANDA Cases - Winter 2021

Federal District Court Cases That Are Filed Pursuant To The Hatch-Waxman Act - This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to...more

Generic Launches - Winter 2021

This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications....more

ANDA Litigation Settlements - Winter 2021

This chart summarizes the case name, drug, patents-in-suit, and publicly available terms for reported settlements in federal district court cases that are filed pursuant to the Hatch-Waxman Act....more

ANDA Approvals - Winter 2021

This chart tracks the date, drug, reference-listed company, and applicant of Abbreviated New Drug Applications and 505(b)(2) Applications receiving final approval by the FDA....more

Par Pharm., Inc. v. Hospira, Inc.

Adrenalin® (epinephrine injection) - Case Name: Par Pharm., Inc. v. Hospira, Inc., No. 2020-1273, 2020 WL 6846347 (Fed. Cir. Nov. 23, 2020) (Circuit Judges Dyk, Taranto, and Stoll presiding; Opinion by Taranto, J.)...more

Bracco Diagnostics Inc. v. Maia Pharms., Inc.

Kinevac® (sincalide) - Case Name: Bracco Diagnostics Inc. v. Maia Pharms., Inc., No. 2020-1387, 2020 WL 7393233 (Fed. Cir. Dec. 17, 2020) (Circuit Judges Lourie, Clevenger, and Chen presiding; Opinion by Lourie, J.)...more

Eli Lilly & Co. v. Apotex, Inc.

Alimta® (pemetrexed disodium) - Case Name: Eli Lilly & Co. v. Apotex, Inc., No. 2020-1328, 2020 WL 7490251 (Fed. Cir. Dec. 21, 2020) (Circuit Judges Prost, Bryson, and Stoll presiding; Opinion by Stoll, J.) (Appeal from...more

Takeda Pharms. U.S.A., Inc. v. Mylan Pharms. Inc.

Colcrys®/colchicine - Case Name: Takeda Pharms. U.S.A., Inc. v. Mylan Pharms. Inc., No. 2020-1407, -1417 (Fed. Cir. July 31, 2020) (Circuit Judges Prost, Newman, and Hughes presiding; Opinion by Prost, C.J.; Dissent by...more

IBSA Institut Biochimique, S.A. v. Teva Pharms. USA, Inc.

Tirosint®/levothyroxine sodium - Case Name: IBSA Institut Biochimique, S.A. v. Teva Pharms. USA, Inc., No. 2019-2400 (Fed. Cir. July 31, 2020) (Circuit Judges Prost, Reyna, and Hughes presiding; Opinion by Prost, C.J.)...more

Bristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc.

Eliquis®/apixaban - Case Name: Bristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc., No. 17-374-LPS (Consolidated), 2020 WL 4500226 (D. Del. Aug. 5, 2020) (Stark, J.)...more

Sun Pharm. Indus. Ltd. v. Saptalis Pharms., LLC

Riomet®/metformin HCl - Case Name: Sun Pharm. Indus. Ltd. v. Saptalis Pharms., LLC, No. 18-648-WCB, 2020 WL 5077412 (D. Del. Aug. 6, 2020) (Bryson, J.)... Drug Product and Patent(s)-in-Suit: Riomet® (metformin HCl);...more

Novartis Pharms. Corp. V. Accord Healthcare INC.

Case Name: Novartis Pharms. Corp. v. Accord Healthcare Inc., No. 18-1043-KAJ (D. Del. August 10, 2020) (Jordan, J.)... Drug Product and Patent(s)-in-Suit: Gilenya® (fingolimod); U.S. Patent No. 9,187,405 (“the ’405...more

Noven Pharm., Inc. v. Amneal Pharms. LLC

Case Name: Noven Pharm., Inc. v. Amneal Pharms. LLC, No. 18-cv-00699 (D. Del. Sept. 2, 2020) (Stark, J.)... Drug Product and Patent(s)-in-Suit: Minivelle® (estradiol); U.S. Patents Nos. 9,833,419 (“the ’419 patent”),...more

Biogen Int’l GmbH v. Amneal Pharmaceuticals LLC

Case Name: Biogen Int’l GmbH v. Amneal Pharmaceuticals LLC, Civ. No. 17-823 (MN), 2020 WL 5549084 (D. Del. Sept. 16, 2020) (Noreika, J.)... Drug Product and Patent(s)-in-Suit: Tecfidera® (dimethyl fumarate (“DMF”)...more

New ANDA Cases - Fall 2020

Federal district court cases that are filed pursuant to the Hatch-Waxman Act - This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to...more

Generic Launches - Fall 2020

This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications. ...more

ANDA Litigation Settlements - Fall 2020

Reported settlements in federal district court cases - This chart summarizes the case name, drug, patents-in-suit, and publicly available terms for reported settlements in federal district court cases that are filed...more

ANDA Approvals - Fall 2020

This chart tracks the date, drug, reference-listed company, and applicant of Abbreviated New Drug Applications and 505(b)(2) Applications receiving final approval by the FDA....more

Celgene Corp. v. Sun Pharma Global FZE

SUBJECT-MATTER JURISDICTION UNDER THE HATCH-WAXMAN ACT DOES NOT REQUIRE (I) A PARAGRAPH IV CERTIFICATION BY THE ANDA HOLDER; OR (II) THE PATENTS-IN-SUIT TO BE LISTED IN THE ORANGE BOOK. Case Name: Celgene Corp. v. Sun...more

Valeant Pharms Int’l, Inc. v. Mylan Pharms Inc.

BECAUSE THE PRIOR ART TAUGHT OVERLAPPING PH RANGES AND STRUCTURALLY SIMILAR COMPOUNDS AS THOSE CLAIMED IN THE PATENT-IN-SUIT, THE FEDERAL CIRCUIT REVERSED SUMMARY JUDGMENT OF NON-OBVIOUSNESS. Case Name: Valeant Pharms...more

85 Results
 / 
View per page
Page: of 4

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide